BRAF and melanoma: However, fair proportions of melanomas are BRAF wild type, NRAS-mutant or TERT-mutant, and hence are insensitive to these vemurafenib.10, 11 Also, metastatic melanomas still need good treatment options, as the underlying mechanisms of melanoma progression and metastasis are not well acknowledged.12 Therefore, it is crucial to discover and identify potential key players in melanoma tumorigenesis for the development of novel cancer therapeutics.